Patients in the simvastatin 10 mg group had significant lower body mass index, cholesterol, triglyceride and LDL-c level at baseline, also had significant lower composite non-fatal MI and non-fatal stroke than other statins group (HR = 0.479, 95% CI 0.31 to 0.74, p = 0.001]. Results: Of the 1,100 type 2 DM patients without prior ASCVD, 446 patients (40.5%) received simvastatin 10 mg and 654 patients (59.5%) received other statins. The association of intensity of statin with cardiovascular events was analyzed with Cox hazard model. Research design and methods We performed a retrospective cohort study of patients with type 2 diabetes (n600 age, 66.3 years men, 68). Data on cardiovascular events, including non-fatal MI and non-fatal stroke were collected. For example, if our ML approach recommends a low-intensity statin, clinicians and patient may wish to explore the potential reasons why a high-intensity statin was not recommended. Objective To examine a relationship between statin intensity and heart failure (HF) incidence in diabetes. Materials and Methods: A retrospective cohort study was conducted on type 2 DM patients without prior history of atherosclerotic cardiovascular disease who attended the endocrine clinic, Faculty of Medicine Vajira Hospital between 1 January 2006 and 30 June 2016, and received statins for primary prevention of ASCVD.
If the increase is mild, you can continue to take the drug. Occasionally, statin use causes an increase in liver enzymes. This can lead to severe muscle pain and kidney damage. Objective: To compare the efficacy of low intensity statin (simvastatin 10 mg) versus moderate and high intensity statins for primary prevention of non-fatal myocardial infarction and non-fatal stroke in type 2 DM patients. Very rarely, high-dose statin use can cause muscle cells to break down and release a protein called myoglobin into the bloodstream.